|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shen CH, Yuan P, Perez-Lorenzo R, Zhang Y,
Lee SX, Ou Y, Asara JM, Cantley LC and Zheng B: Phosphorylation of
BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation.
Mol Cell. 52:161–172. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang H, Koo CY, Stebbing J and Giamas G:
The dual function of KSR1: a pseudokinase and beyond. Biochem Soc
Trans. 41:1078–1082. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kortum RL, Fernandez MR, Costanzo-Garvey
DL, Johnson HJ, Fisher KW, Volle DJ and Lewis RE: Caveolin-1 is
required for kinase suppressor of Ras 1 (KSR1)-mediated
extracellular signal-regulated kinase 1/2 activation,
H-RasV12-induced senescence, and transformation. Mol Cell Biol.
34:3461–3472. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Llobet D, Eritja N, Domingo M, Bergada L,
Mirantes C, Santacana M, Pallares J, Macià A, Yeramian A, Encinas
M, et al: KSR1 is overexpressed in endometrial carcinoma and
regulates proliferation and TRAIL-induced apoptosis by modulating
FLIP levels. Am J Pathol. 178:1529–1543. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Razidlo GL, Johnson HJ, Stoeger SM, Cowan
KH, Bessho T and Lewis RE: KSR1 is required for cell cycle
reinitiation following DNA damage. J Biol Chem. 284:6705–6715.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lozano J, Xing R, Cai Z, Jensen HL,
Trempus C, Mark W, Cannon R and Kolesnick R: Deficiency of kinase
suppressor of Ras1 prevents oncogenic ras signaling in mice. Cancer
Res. 63:4232–4238. 2003.PubMed/NCBI
|
|
8
|
Cullis J, Meiri D, Sandi MJ, Radulovich N,
Kent OA, Medrano M, Mokady D, Normand J, Larose J, Marcotte R, et
al: The RhoGEF GEF-H1 is required for oncogenic RAS signaling via
KSR-1. Cancer Cell. 25:181–195. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stoeger SM and Cowan KH: Characterization
of kinase suppressor of Ras-1 expression and anticancer drug
sensitivity in human cancer cell lines. Cancer Chemother Pharmacol.
63:807–818. 2009. View Article : Google Scholar
|
|
10
|
Salerno M, Palmieri D, Bouadis A,
Halverson D and Steeg PS: Nm23-H1 metastasis suppressor expression
level influences the binding properties, stability, and function of
the kinase suppressor of Ras1 (KSR1) Erk scaffold in breast
carcinoma cells. Mol Cell Biol. 25:1379–1388. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu SQ, Yu JP, Yu HG, Lv P and Chen HL:
Activation of Akt and ERK signalling pathways induced by etoposide
confer chemoresistance in gastric cancer cells. Dig Liver Dis.
38:310–318. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ude C, Schubert-Zsilavecz M and Wurglics
M: Ginkgo biloba extracts: A review of the pharmacokinetics of the
active ingredients. Clin Pharmacokinet. 52:727–749. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tsai JR, Liu PL, Chen YH, Chou SH, Yang
MC, Cheng YJ, Hwang JJ, Yin WH and Chong IW: Ginkgo biloba extract
decreases non-small cell lung cancer cell migration by
down-regulating metastasis-associated factor heat-shock protein 27.
PLoS One. 9:e913312014. View Article : Google Scholar
|
|
14
|
Chen XH, Miao YX, Wang XJ, Yu Z, Geng MY,
Han YT and Wang LX: Effects of Ginkgo biloba extract EGb761 on
human colon adenocarcinoma cells. Cell Physiol Biochem. 27:227–232.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
El Mesallamy HO, Metwally NS, Soliman MS,
Ahmed KA and Abdel Moaty MM: The chemopreventive effect of Ginkgo
biloba and Silybum marianum extracts on hepatocarcinogenesis in
rats. Cancer Cell Int. 11:382011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Park YJ, Kim MJ, Kim HR, Yi MS, Chung KH
and Oh SM: Chemopreventive effects of Ginkgo biloba extract in
estrogen-negative human breast cancer cells. Arch Pharm Res.
36:102–108. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Koltermann A, Liebl J, Fürst R, Ammer H,
Vollmar AM and Zahler S: Ginkgo biloba extract EGb 761 exerts
anti-angiogenic effects via activation of tyrosine phosphatases. J
Cell Mol Med. 13:2122–2130. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiang XY, Qian LP, Zheng XJ, Xia YY, Jiang
YB and Sun Y: Interventional effect of Ginkgo biloba extract on the
progression of gastric precancerous lesions in rats. J Dig Dis.
10:293–299. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu AH, Chen HS, Sun BC, Xiang XR, Chu YF,
Zhai F and Jia LC: Therapeutic mechanism of Ginkgo biloba exocarp
polysaccharides on gastric cancer. World J Gastroenterol.
9:2424–2427. 2003.PubMed/NCBI
|
|
20
|
Mao YB, Liu SQ, Tan L, Zhou Q and Huang
JA: EGb761 enhances cisplatin and etoposide-induced apoptosis of
human gastric cancer SGC-7901 cells. Shijie Huaren Xiaohua Zazhi.
21:3330–3337. 2013.In Chinese.
|
|
21
|
Liu SQ, Yu JP, Chen HL, Luo HS, Chen SM
and Yu HG: Therapeutic effects and molecular mechanisms of Ginkgo
biloba extract on liver fibrosis in rats. Am J Chin Med. 34:99–114.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kortum RL and Lewis RE: The molecular
scaffold KSR1 regulates the proliferative and oncogenic potential
of cells. Mol Cell Biol. 24:4407–4416. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gramling MW and Eischen CM: Suppression of
Ras/Mapk pathway signaling inhibits Myc-induced lymphomagenesis.
Cell Death Differ. 19:1220–1227. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fukui H, Zhang X, Sun C, Hara K, Kikuchi
S, Yamasaki T, Kondo T, Tomita T, Oshima T, Watari J, et al: IL-22
produced by cancer-associated fibroblasts promotes gastric cancer
cell invasion via STAT3 and ERK signaling. Br J Cancer.
111:763–771. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xing HR, Cordon-Cardo C, Deng X, Tong W,
Campodonico L, Fuks Z and Kolesnick R: Pharmacologic inactivation
of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic
cancer. Nat Med. 9:1266–1268. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Smith JV and Luo Y: Studies on molecular
mechanisms of Ginkgo biloba extract. Appl Microbiol Biotechnol.
64:465–472. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mohanta TK, Tamboli Y and Zubaidha PK:
Phytochemical and medicinal importance of Ginkgo biloba L. Nat Prod
Res. 28:746–752. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang Y, Chen AY, Li M, Chen C and Yao Q:
Ginkgo biloba extract kaempferol inhibits cell proliferation and
induces apoptosis in pancreatic cancer cells. J Surg Res.
148:17–23. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kang JW, Kim JH, Song K, Kim SH, Yoon JH
and Kim KS: Kaempferol and quercetin, components of Ginkgo biloba
extract (EGb 761), induce caspase-3-dependent apoptosis in oral
cavity cancer cells. Phytother Res. 24(Suppl 1): S77–S82. 2010.
View Article : Google Scholar
|
|
30
|
Akhiani AA, Werlenius O, Aurelius J,
Movitz C, Martner A, Hellstrand K and Thorén FB: Role of the ERK
pathway for oxidant-induced parthanatos in human lymphocytes. PLoS
One. 9:e896462014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang J, Lin D, Peng H, Huang Y, Huang J
and Gu J: Cancer-derived immunoglobulin G promotes tumor cell
growth and proliferation through inducing production of reactive
oxygen species. Cell Death Dis. 4:e9452013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li W, Wu Z, Ma Q, Liu J, Xu Q, Han L, Duan
W, Lv Y, Wang F, Reindl KM, et al: Hyperglycemia regulates
TXNIP/TRX/ROS axis via p38 MAPK and ERK pathways in pancreatic
cancer. Curr Cancer Drug Targets. 14:348–356. 2014. View Article : Google Scholar : PubMed/NCBI
|
